首页|生物医药企业在安全标准化基础上建设双重预防机制的思考

生物医药企业在安全标准化基础上建设双重预防机制的思考

Consideration on Establishing Double Prevention Mechanism Based on Safety Standardization in Bio-pharmaceutical Enterprises

扫码查看
本文从生物医药企业的安全管理现状出发,分析现有安全标准化管理中需要提升的关键要点,探讨双重预防机制建设的必要性及其方向,将风险分析、安全检查、安全责任制与安全操作规程进行结合,实现一体化安全管理,逐步提高生物医药企业的安全管理水平,对生物医药企业安全管理有重要的理论和实践意义.
Starting from the current situation of safety management in biopharmaceutical enterprises,analyze the key areas that need to be improved in existing safety standardization management,exploring the necessity and direction of building a dual prevention mechanism,integrate risk analysis,safety inspections,safety responsibility systems,and safety operating procedures,achieve integrated safety management,gradually improve the safety management level of bio-pharmaceutical enterprises.This study has important theoretical and practical significance for the safety management of biomedical enterprises.

bio-pharmaceutical enterprisessafety standardizationdouble prevention mechanismsafety responsibility systemhidden dangers investigation

林小瑞、张铭润、周玮、邹俊如、黄成、郑俊杰

展开 >

中国医学科学院医学生物学研究所,云南 昆明 650118

生物医药企业 安全标准化 双重预防机制 安全责任制 隐患排查

2024

中国科技纵横
中国民营科技促进会

中国科技纵横

影响因子:0.102
ISSN:1671-2064
年,卷(期):2024.(21)